Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.
نویسندگان
چکیده
Four male transsexual subjects were given a superactive luteinizing hormone-releasing hormone (LHRH) analogue, D-tryptophan-6-LHRH at daily doses of 100 micrograms for 3--6 mo. A decrease in beard growth, acne, and erectile potency was noted; the latter was documented objectively with the recordings of nocturnal penile tumescence episodes. Plasma testosterone and dihydrotestosterone levels fell to castrate values; basal prolactin and luteinizing hormone levels showed a small decline, whereas the acutely releasable luteinizing hormone was significantly suppressed. A rise of plasma testosterone from castrate to normal levels was demonstrable with the use of human chorionic gonadotropin. Discontinuation of treatment led to a normalization of erectile potency and plasma testosterone. The suppression of Leydig cell function by D-tryptophan-6-LHRH might have wide application in reproductive biology and in endocrine-dependent neoplasia (where it could replace surgical castration).
منابع مشابه
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
Intramuscular injection of [6-D-tryptophan]-luteinizing hormone-releasing hormone [( D-Trp6]LH-RH) in microcapsules of poly(DL-lactide-co-glycolide), designed to release a controlled dose of the peptide over a 30-day period, decreased the weights of androgen-dependent Dunning prostate tumors in rats and suppressed serum testosterone levels more effectively than daily subcutaneous administration...
متن کاملHealth related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.
PURPOSE Health related quality of life was assessed in patients with prostate cancer on androgen suppression therapy re-dosed based on serum testosterone, and observations were confirmed regarding the safety, efficacy and cost per patient treated with this method of re-dosing luteinizing hormone-releasing hormone agonists. MATERIALS AND METHODS The study comprised 22 patients with prostate ca...
متن کاملAltered cognitive function in men treated for prostate cancer with leutinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled study.
OBJECTIVE To report the first systematic investigation of the cognitive effects of luteinizing hormone-releasing hormone (LHRH) analogues in male patients, as LHRH analogues have been associated with memory impairments in women using these drugs for gynaecological conditions. PATIENTS AND METHODS Eighty-two men with extraprostatic prostate cancer were randomly assigned to receive either conti...
متن کاملThe double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks.
In their review article, Drs. Crawford and Moul seek to describe the cardiovascular (CV), renal, and pulmonary complications associated with the use of long-term androgen deprivation therapy (ADT) in men with prostate cancer.[1] Furthermore, they attempt to determine whether there is a difference in CV and renal complications between different types of ADT, including luteinizing hormone–releasi...
متن کاملP-152: Expression of Recombinant Human Luteinizing Hormone (hLH) in CHO Cells
Background: Human luteinizing hormone (hLH) stimulates steroid biosynthesis of the ovary, triggers ovulation and prepares androgen production of testicular Leydig cells. LH belongs to the family of glycoprotein hormones that are heterodimers consisting of a common α-subunit and specific β-subunit. hLH is necessary for clinical and infertility treatment. Recombinant DNA technology provides a use...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of clinical investigation
دوره 68 3 شماره
صفحات -
تاریخ انتشار 1981